ARM vs MRNA

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Aug 09, 2026

ARM

55.6
AI Score
VS
ARM Wins

MRNA

55.2
AI Score

Investment Advisor Scores

ARM

56score
Recommendation
HOLD

MRNA

55score
Recommendation
HOLD

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric ARM MRNA Winner
Revenue 1.29B 534.00M ARM
Net Income 270.00M -2.13B ARM
Net Margin 20.9% -397.9% ARM
Operating Income 91.00M -2.20B ARM
ROE 3.1% -31.4% ARM
ROA 2.4% -19.4% ARM
Total Assets 11.20B 10.96B ARM
Cash 3.06B 1.72B ARM
Current Ratio 5.25 2.29 ARM
Free Cash Flow 705.00M -1.25B ARM

Relative Price Performance (Last 90 Days)

ARM 1M: +12.6% · 3M: -10.2% MRNA 1M: +40.0% · 3M: +156.6%

Current Technical Phase

ARM

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 53

RSI (14): 53.2 · Price: $294.37

MRNA

Markup
Hold / add on dips

Price above SMA50, rising 50-day trend (49.6% over 20 days), RSI 64

RSI (14): 63.6 · Price: $196.48

Fundamentals Snapshot

Metric ARM MRNA
Market Cap — —
Forward P/E 137.6 -41.0
Trailing P/E 311.9 —
Revenue (TTM) — —
Revenue Growth 0.2% 0.0%
Gross Margin 1.0% -0.7%
Operating Margin 0.1% -5.6%
EPS 0.97 -7.36
Dividend Yield — —

Frequently Asked Questions

Based on our detailed analysis, ARM is currently the stronger investment candidate, winning 10 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.